Hospital
Providence Health & Services - Wa
Providence Health & Services - Wa was paid $10.96M by Medicaid between Jan 2018 and Dec 2024, across 102 billing codes. Its largest line is 74177, Computed tomography, abdomen and pelvis; with contrast material — 16% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH & SERVICES - WA
CHEWELAH, WA 99109
CHEWELAH, WA 99109
33aNPI1750532321assigned 10/01/2008
33bProvider typeCritical Access Hospital
28Total paid$10.96M
24GClaims113,898
24DCodes billed102
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Washington
Rank by total paid#13 of 30
Median peer was paid$9.10M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,218 | $864K | |
| 2019 | 9,940 | $682K | |
| 2020 | 14,045 | $1.23M | |
| 2021 | 18,574 | $1.69M | |
| 2022 | 20,812 | $2.68M | |
| 2023 | 19,703 | $2.00M | |
| 2024incomplete | 18,606 | $1.81M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 16% | 984 | 943 | $1.81M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 4,420 | 3,265 | $1.66M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 5,437 | 4,199 | $1.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 7,141 | 6,061 | $1.20M |
| 80053 | Comprehensive metabolic panel | 3.8% | 8,788 | 7,390 | $412K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 9,203 | 7,655 | $304K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.7% | 3,075 | 2,548 | $293K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 636 | 608 | $286K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.6% | 2,645 | 2,214 | $280K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 2,027 | 1,353 | $272K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.3% | 4,643 | 1,843 | $248K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 6,419 | 2,495 | $228K |
90 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 2,311 | $179K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 2,931 | $172K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 1,706 | $136K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 1,228 | $132K |
| 81001 | 1.0% | 4,561 | $115K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,344 | $101K |
| 96376 | <1% | 762 | $98K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,420 | $97K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 721 | $86K |
| 83605 | <1% | 2,462 | $84K | |
| 84484 | <1% | 2,243 | $79K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,221 | $78K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,180 | $75K |
| 83690 | <1% | 1,905 | $70K | |
| 87631 | <1% | 811 | $68K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 515 | $65K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,568 | $60K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,825 | $53K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,037 | $52K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 619 | $52K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 42 | $52K |
| 82077 | <1% | 499 | $43K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 998 | $40K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,840 | $39K |
| 80050 | General health panel | <1% | 252 | $39K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 160 | $35K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 370 | $32K |
| 81025 | <1% | 993 | $31K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,228 | $30K |
| 83735 | <1% | 1,654 | $27K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 189 | $27K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 194 | $25K |
| 72100 | <1% | 132 | $24K | |
| 83880 | <1% | 557 | $23K | |
| 80306 | <1% | 1,482 | $23K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 337 | $21K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,179 | $19K |
| 85610 | <1% | 1,125 | $19K | |
| 73630 | <1% | 123 | $19K | |
| 80061 | Lipid panel | <1% | 456 | $15K |
| 87040 | <1% | 462 | $15K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 194 | $15K |
| 85379 | <1% | 295 | $12K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 104 | $11K |
| 86140 | <1% | 353 | $10K | |
| 73030 | <1% | 70 | $10K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 203 | $7K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 60 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 188 | $7K |
| 84439 | <1% | 207 | $7K | |
| 73562 | <1% | 40 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 318 | $6K |
| 85652 | <1% | 237 | $6K | |
| 87077 | <1% | 83 | $5K | |
| 97161 | <1% | 78 | $5K | |
| 73610 | <1% | 32 | $5K | |
| 82962 | <1% | 426 | $5K | |
| 82150 | <1% | 108 | $5K | |
| 80179 | <1% | 44 | $4K | |
| 80143 | <1% | 43 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 90 | $3K |
| 97162 | <1% | 38 | $3K | |
| 73130 | <1% | 18 | $2K | |
| 90715 | <1% | 13 | $2K | |
| 85027 | <1% | 87 | $2K | |
| 81003 | <1% | 150 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 86 | $2K |
| 87634 | <1% | 14 | $2K | |
| 73110 | <1% | 13 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 50 | $2K |
| 87400 | <1% | 24 | $1K | |
| 82607 | <1% | 27 | $1K | |
| 82805 | <1% | 25 | $1K | |
| 73502 | <1% | 12 | $1K | |
| 85730 | <1% | 65 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 60 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 192 | $959.29 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 57 | $884.58 |
| 82746 | <1% | 14 | $742.05 | |
| 86803 | <1% | 13 | $643.15 | |
| 87205 | <1% | 27 | $610.28 | |
| 85651 | <1% | 25 | $531.48 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 16 | $530.06 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 85 | $480.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 27 | $480.25 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 27 | $394.26 |
| 94760 | <1% | 17 | $341.05 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $275.48 |
| A9270 | Non-covered item or service | 0% | 444 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY FOR ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.